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Abstract
Background: TB and HIV form a deadly synergy in much of the developing world, especially
Africa. Interventions to reduce the impact of these diseases at community level are urgently
needed. This paper presents the design of a community randomised trial to evaluate the impact of
two complex interventions on the prevalence of tuberculosis (TB) in high HIV prevalence settings
in Zambia and South Africa.
Methods: The interaction between TB and HIV is reviewed and possible interventions that could
reduce the prevalence of TB in HIV-endemic populations are discussed. Two of these interventions
are described in detail and the design of a 2 × 2 factorial community randomised trial to test these
interventions is presented. The limitations and challenges of the design are identified and discussed.
Conclusion: There is an urgent need to reduce the prevalence of TB in communities highly
affected by HIV. Potential interventions are complex and require innovative trial designs to provide
the rigorous evidence needed to inform health policy makers and to ensure that resources are used
optimally.
Trial Registration: Number: ISRCTN36729271
Background
Tuberculosis (TB) incidence is increasing in much of sub-
Saharan Africa, largely due to the high prevalence of HIV
infection. International TB control strategies rely on self-
presentation of cases to the health services, diagnosis by
sputum smear microscopy and the use of a 6–8 month
course of multi-drug therapy to cure the disease[1]. How-
ever these strategies are currently failing to control TB in
high HIV prevalence settings, due both to the massive bur-
den of disease and the inadequacy of existing health sys-
tems to find and cure infectious cases coupled with the
continuing stigma and denial that surround HIV and
TB[2].
The Zambia/South Africa TB and AIDS Reduction (ZAM-
STAR) study aims to use existing tools for diagnosis and
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control strategies to determine whether these can reduce
the prevalence of TB and HIV at community level.
Rationale for ZAMSTAR
The first mechanism by which prevalence of TB could be
reduced is through more efficient detection and treatment
of infectious cases of TB. Prior to the HIV epidemic, a large
body of work provided the backbone for the DOTS strat-
egy, which uses passive case-finding to detect TB cases[3].
Recent work highlights the importance of case-finding
and the need to adapt the existing approach to incorpo-
rate a more aggressive form of case-detection. The chal-
lenge in poorly-resourced settings is how to achieve this
without overburdening an already overstretched health
service. Sustainable case-finding will need to involve col-
laboration between the formal health services, other gov-
ernment sectors, community based organisations and the
community.
Reducing the reactivation of latent TB infection by preven-
tive therapy and improving the immune function of HIV-
infected individuals is another mechanism that could
reduce TB prevalence. Randomised trials in developing
countries have demonstrated the efficacy of isoniazid in
preventing TB in HIV-positive subjects at the individual
level[4], but its population-level effectiveness as a TB con-
trol measure in HIV prevalent settings has not been
proven. Feasibility studies have demonstrated that the
main barriers to the successful implementation of this
intervention are the difficulties in excluding active TB and
low adherence to the course of treatment[5]. For the inter-
vention to be effective at community level, uptake must be
increased. Uptake is currently hampered by lack of knowl-
edge of HIV status and poor access to counselling, testing
and care as well as by poverty and rural deprivation. TB
preventive therapy is also recommended for the house-
hold contacts of cases of infectious TB but in most coun-
tries is not implemented due to the low priority given to
this intervention, lack of available health workers and
limited availability of drugs.
HIV infection is widely acknowledged as the driving force
behind the current TB epidemic in Southern Africa. Long
term control of TB must include addressing the problem
of HIV prevention. Proven interventions to reduce the
incidence of HIV at a community level are disappointingly
few. Provision of voluntary counselling and testing (VCT)
has been promoted as an important step in supporting
individuals to change behaviour by facilitating knowledge
of HIV status. Few trials have used HIV incidence as an
end point, although a recent study in Harare among fac-
tory workers showed that despite good uptake of VCT HIV
incidence was not reduced[6]. Other studies have shown
some evidence of behaviour change in HIV-positive indi-
viduals but little change has been seen in HIV-negative
ones[7]. VCT has been shown to be most effective when
offered to couples, since this allows discordant couples to
make realistic plans to reduce the risk of HIV transmis-
sion[8,9]. Antiretroviral drugs are rapidly becoming more
available in developing countries and it is hoped that the
increased availability of these drugs may increase uptake
of HIV testing and counselling and also reduce transmis-
sion of HIV by reducing viral load. This theory is
unproven, however, and in wealthier countries, already
using antiretrovirals, there is evidence that sexual behav-
iour has become more, rather than less, risky since their
use became widespread and that HIV incidence may be
increasing[10].
Finally, stigma is recognised as a barrier for individuals to
access diagnosis and care for both TB and HIV. Studies
have demonstrated that stigma prevents people (includ-
ing TB patients or suspects) from: accessing health care,
learning their HIV status, disclosing their HIV status to
partners, changing unsafe behaviour, and caring for peo-
ple living with HIV/AIDS (PLWHA), and that the most
extreme forms of stigma are often found in households
and health facilities [11].
ZAMSTAR has addressed these issues by developing two
interventions that combine all of the above strategies and
that can be applied at community level. These interven-
tions are community-based enhanced case finding for
tuberculosis (ECF) and household counselling and provi-
sion of combined TB/HIV prevention services at the
household level (HH). The effectiveness of these interven-
tions at population level will be evaluated through a com-
munity-randomised trial with a 2 × 2 factorial design.
Design
Study setting
The study is being conducted in Zambia and South Africa,
two countries highly affected by the TB and HIV epidem-
ics, and forms part of the CREATE consortium http://
www.tbhiv-create.org/ZAMSTAR.html. Study communi-
ties have been selected based on TB notification rates
greater than 400/100,000 per annum, high HIV seroprev-
alence and proximity to a TB diagnostic centre. The com-
munities selected are in five provinces of Zambia and in
Western Cape province of South Africa and include both
urban and rural communities (Fig 1).
Design of the interventions
Enhanced case finding intervention (ECF)
Three components of ECF are being employed at the com-
munity and health centre levels.Page 2 of 10
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Map of ZAMSTAR communitiesFigure 1
Map of ZAMSTAR communities.
Trials 2008, 9:63 http://www.trialsjournal.com/content/9/1/63Open laboratory access at health centre
Individuals are able to directly access sputum smear exam-
ination for TB at the health centre laboratories, without
having to see a clinician or be referred for this service. This
service is available continuously and is widely advertised
in the community.
Community mobilisation and mobile sputum collection points
Community mobilisation is conducted to educate the
community about TB and its diagnosis. Mobile sputum
collection points are set up at strategic points in the com-
munity where symptomatic members of the public are
asked to submit sputum samples on the spot and to return
the following day for the results. The location of these
sputum collection points ensure that all members of the
community have access to sputum examination within 30
minutes walk of their home at least three times per year.
School mobilisation campaign
All schools in the community receive an annual education
programme about HIV and TB. Children are encouraged
to take messages about the transmission and diagnosis of
TB home so that family members who have been cough-
ing for more than three weeks can submit sputum samples
at collection points set up in the schools or at the clinic.
Any cases of TB found by the ECF activities are treated via
the routine clinic-based DOTS services.
Household intervention (HH)
All TB cases diagnosed and notified through the TB con-
trol programme are invited to participate in this interven-
tion. All households of TB patients receive information
about HIV and TB within the home from a specially
trained counsellor. The household members are encour-
aged to be tested for HIV and screened for TB. A "shared
confidentiality" is encouraged between household mem-
bers to facilitate open discussion of the outcome of the
investigations. The household is also encouraged to take
responsibility for the member diagnosed with TB and to
supervise and encourage treatment compliance. House-
hold members with HIV who do not have active tubercu-
losis diagnosed are offered TB preventive therapy, as are
all children under the age of 6 years, in keeping with
national policies (although these are otherwise poorly
implemented). Adherence is supported within the family,
as well as by the routine treatment support service of the
district. All HIV-positive household members will be
encouraged to obtain HIV care including antiretroviral
therapy (ART) which is provided by the health centres or
district hospitals in all of the communities.
Standard TB/HIV control practice
In all arms of the study, standard TB control practices are
supported and, where necessary, improved such that all
diagnostic centres are applying a model DOTS pro-
gramme. Integration of TB and HIV services will be facili-
tated including diagnostic counselling and testing for HIV
in TB patients, referral networks to enable TB patients to
access HIV care, screening of HIV positive individuals for
TB and the provision of isoniazid preventive therapy for
eligible individuals[12].
Design of the randomised trial
The interventions are being evaluated by means of a 2 × 2
factorial community randomised trial.
The primary study questions are:
• Does enhanced tuberculosis case finding (ECF), by a
strategy of community mobilisation and enhanced access
to sputum microscopy, reduce prevalence of tuberculosis
in the community?
• Does a strategy of combined TB/HIV activities at the
household level (HH), that includes active case-finding,
isoniazid preventive therapy, and psychosocial and adher-
ence support for both treatment and prevention of tuber-
culosis and HIV, reduce prevalence of tuberculosis in the
community?
The unit of randomisation will be the population access-
ing one TB diagnostic centre (which will be known as the
"community"). A 2 × 2 factorial design will be used so that
there will be four arms:
Arm 1: Standard TB/HIV Control activities at the clinic
only
Arm 2: Standard TB/HIV Control activities at the clinic
plus ECF
Arm 3: Standard TB/HIV Control activities at the clinic
plus HH
Arm 4: Standard TB/HIV Control activities at the clinic
plus ECF plus HH
The primary analysis will be a comparison of ECF Vs no
ECF (arms 2 & 4 vs arms 1 & 3) and of HH Vs no HH
(arms 3 & 4 vs arms 1 & 2). This allows the questions
posed in the specific objectives to be addressed. The facto-
rial design will also allow arm 4 to be compared directly
to arm 1, referred to as the control arm in this paper, to
address the question:
• What is the overall effect of the combined interventions
(ECF+HH) on the prevalence of tuberculosis in the com-
munity?Page 4 of 10
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in each community will be followed for the duration of
the interventions to allow analysis of household-level out-
comes, using both epidemiological and social science
methods.
Outcome measures
The primary outcome for the study is the prevalence of
tuberculosis after three years of intervention, measured
through surveys of a random sample of adults (aged > 15
years) from each community.
Secondary outcomes at community level are:
• Incidence of tuberculosis infection measured by repeat
tuberculin skin testing (TST) in primary school children
found to be TST negative at baseline.
• Tuberculosis treatment outcomes (Cure, Completed
treatment, Failed, Defaulted, Died, Transferred) measured
by cohort analysis of strengthened tuberculosis register
data.
• Additional tuberculosis cases detected by ECF and HH
measured using the strengthened laboratory register.
• Uptake of HIV testing and counselling and uptake of
and adherence to tuberculosis preventive therapy meas-
ured using the testing and counselling register.
• Costs of each component of the intervention and cost-
effectiveness comparisons of strategies to find and prevent
cases of tuberculosis and HIV.
Secondary outcomes at household level, as measured on a
cohort of households are:
• Cumulative HIV incidence measured by serial HIV test-
ing among those over 15 years old.
• Uptake of HIV testing and counselling and uptake and
adherence to tuberculosis preventive therapy among
household members of TB patients
• Tuberculosis transmission within the household meas-
ured by TST and Quantiferon-Gold IT conversion rates
• Cumulative incidence of tuberculosis disease in house-
hold contacts
• Stigma levels measured using a quantitative stigma score
Outcome measurement
Baseline assessment of communities
In order to stratify and restrict the randomisation of com-
munities a baseline assessment was conducted by collat-
ing information on TB notification rates, TB treatment
outcomes, HIV prevalence data and the prevalence of
tuberculous infection in school children (see below). In
addition to the quantitative baseline assessment, a rapid
qualitative appraisal of the communities was conducted.
This appraisal involved community mapping, observation
and key informant interviews to understand the domains
of TB in the local community including population move-
ment, congregation points, beliefs and knowledge about
TB and HIV as well as general socio-economic informa-
tion about the communities
Tuberculin Skin Testing
Baseline measurement of tuberculous infection in all
ZAMSTAR communities was estimated by means of tuber-
culin skin testing (TST) surveys among primary school
children[13]. These community-wide surveys served three
objectives: to characterise ZAMSTAR communities, with
regards to TB infection, in relative terms; to inform the
randomisation of the communities into the four interven-
tion arms; and to provide data for one of the community-
wide secondary outcomes. The design as well as results
from these surveys will be described in a separate paper.
The 22,000 children involved in these surveys are being
followed up for the three years of the intervention and
will be retested at the end of the study to measure the inci-
dence of TB infection in those who were uninfected at
baseline.
TB prevalence surveys
The primary outcome of the study will be measured by
conducting TB prevalence surveys on 5000 randomly
selected members of each community. The methodology
to be used for these surveys will involve TB culture of 1
respiratory specimen from each adult. The prevalence of
TB will be measured as the proportion of these samples
that grow Mycobacterium tuberculosis using a standard liq-
uid culture technique (MGIT, Becton Dickinson).
Secondary outcome cohort (SOC)
150 consecutive TB patients and their households are
being recruited in each community and asked to complete
a baseline questionnaire containing demographic and
specific TB and HIV data as well as questions about stigma
relating to TB and HIV. Adults are asked to provide a
serum sample to test for HIV and both adults and children
are tested for TB infection. This cohort will be visited after
eighteen months and again after three years of the inter-
vention to allow measurement of HIV incidence, the inci-Page 5 of 10
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changes in perceptions of stigma.
TB/HIV indicators
In each community TB/HIV programme indicators as
described in the WHO guide to Monitoring and Evalua-
tion of TB/HIV collaborative Activities [14] will be col-
lected throughout the study period. These will provide the
secondary outcome measurements at community level.
Sample size
Based on data from prevalence studies in Cape Town [15]
and WHO estimates of tuberculosis prevalence[16] we
assumed a prevalence of tuberculosis in the control arm of
1%. We powered our study in order to be able to detect a
30% reduction in prevalence of tuberculosis due to each
intervention individually and a further 30% reduction in
tuberculosis prevalence when the two interventions are
combined. To achieve 80% power of detecting a signifi-
cant difference (2-sided p < 0.05), an assumed between-
community coefficient of variation k = 0.20 and 5,000
individuals sampled per community (Tab 1 and figure 2)
we would need 12 communities in each arm. The total
sample size will therefore be 24 communities, 6 in each of
the four arms[17].
The two primary study questions will be answered by
comparing 12 communities with the other 12 (e.g. non-
ECF arms 1 & 3 Vs. ECF arms 2 & 4 or non-HH arms 1 &
2 Vs. HH arms 3 & 4), allowing for the factorial design this
means that we assume a TB prevalence of 1% in the con-
trol arm (arm1), 0.7% in single intervention arms (arm 2
and arm 3) and 0.49% in the arm with both interventions
(arm 4). Overall, the primary study comparisons will
therefore be able to detect the 30% reduction in TB prev-
alence from 0.85% to 0.595%.
For the secondary outcome of cumulative incidence of
tuberculosis infection over three years of intervention, as
measured by TSTs, we wish to detect a 30% reduction
associated with either the ECF or HH intervention. The
sample size is calculated to provide 80% power of detect-
ing this difference (two-sided p < 0.05,) on the assump-
tion that there will be 12 communities in each of the arms
for the two main comparisons and with k = 0.20. Under
these assumptions, and with an assumed 3% cumulative
incidence of tuberculosis infection over three years (at 1%
annual risk of infection) in the control arm and allowance
for 20% loss to follow-up, we will need to initially recruit
800 children in each community.
HIV incidence will be measured in the secondary outcome
cohort of 150 TB patients and their households per com-
Table 1: Sample size calculations for power of 80% (two-sided, 5% significance level), based on sample of 5000 individuals per 
community and allowing for 20% losses, for each of the main comparisons (ECF vs non-ECF & HH vs non-HH)
Prevalence (%) in Control arm Reduction in Prevalence due to each 
intervention (ECF or HH) individually
Prevalence (%) in ECF or HH arm Overall number of communities 
needed (equally split into 4 arms)
k = 0.15
0.6 30% 0.42 24
0.8 30% 0.56 20
1.0 30% 0.7 18
1.0 20% 0.8 41
1.0 10% 0.9 168
k = 0.2
0.6 30% 0.42 30
0.8 30% 0.56 26
1.0 30% 0.7 24
1.0 20% 0.8 54
1.0 10% 0.9 227
k = 0.25
0.6 30% 0.42 45
0.8 30% 0.56 42
1.0 30% 0.7 39
1.0 20% 0.8 93
1.0 10% 0.9 398
k = between-cluster coefficient of variationPage 6 of 10
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3 HIV negative adults at the start of the study. Allowing for
loss to follow-up of 20%, this sample size will provide
80% power to detect a reduction in cumulative HIV inci-
dence of 40%, (2-sided p <0.05)) assuming HIV incidence
in those individuals not receiving the intervention is at
least 0.7% per year (cumulative incidence 2.1% over 3
years).
Randomization
Due to the small number of communities in the study we
stratified randomisation by country and the prevalence of
TB infection (as measured by baseline TST surveys and cat-
egorised as high/low within countries). We used restricted
randomisation to ensure balance on TST prevalence, HIV
prevalence, urban/rural, social context and geographical
location. A two-stage public randomisation ceremony was
conducted to select one of the possible allocations for the
study arms and then to allocate the interventions to those
study arms. The design and results of this allocation pro-
cedure have been described in another paper [18].
Analytic plan
As a community randomised trial ZAMSTAR will be ana-
lysed both at the cluster level, by deriving summary statis-
tics for each community, and at the individual level using
data from each individual in each community. For these
analyses statistical methods that take account of between-
and within-cluster variation will be used. The analysis will
give each community equal weight. There are three inter-
vention comparisons that will be made assessing the
effects of ECF alone (12 Vs 12 communities), HH alone
(12 Vs 12 communities) and ECF plus HH combined (6
Vs 6 communities). Impact measures of the above com-
parisons will be based on ratios.
To account for the study design, suitable generalized lin-
ear models will be used, where appropriate, to allow for
Graph showing the effects on sample size of different inter-cluster coefficients of variation (k)Figure 2
Graph showing the effects on sample size of different inter-cluster coefficients of variation (k).
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alence, incidence) the overall risk/rate for each cluster will
be calculated. Risks/rates for each cluster will be shown,
by strata and arm. A log transformation to normalise data
will be applied to the risk/rate for each cluster. The mean
and SD of these log risks/rates will be used to obtain the
geometric mean (if the log transformation is clearly inap-
propriate the arithmetic mean will be used instead) and
associated 95% CI for each intervention arm of the study.
Linear regression of the log mean risk/rate on strata and
arm will be used to estimate the relative risk/rate and 95%
CI associated with the intervention. The approximate var-
iance for the mean risks/rates ratio is obtained based on
the residual mean square from a two-way analysis of vari-
ance (ANOVA) of community log-risk on stratum and
study arm. A 95% CI for the relative risk/rate will be cal-
culated from this variance using a t-statistic with 16
degrees of freedom (df) for the two main comparisons
and 10 df for the comparison of arm 4 Vs arm 1.
For the continuous outcomes such as intervention costs
and stigma levels, the overall mean for each community
will be calculated, and means for each community will be
shown, by strata and arm. The arithmetic mean and SD of
these mean scores/numbers and associated 95% CI for
each intervention arm of the study will be calculated. Lin-
ear regression of the mean score/number on strata and
arm (2-way ANOVA on intervention and strata) will be
used to estimate the difference in score/number and 95%
CI associated with the intervention.
Apart from calculation of crude effects, adjusted analyses
to account for potential confounding effects will also be
performed. Potential confounding factors will include
age, sex, TB infection prevalence (as calculated by baseline
TST surveys) as well as other factors found to differ
between study arms at baseline and which may be risk fac-
tors for a particular outcome. For the binary outcomes
(prevalence, incidence) logistic regression will be used to
adjust for confounders at the individual level and cluster
level, adopting a two-stage process. The regression model
will include terms for the adjustment factors and strata,
but not study arm. For each community the fitted model
will be used to obtain the ratio of observed (O) to
expected (E) or O/E events, and a log transformation
applied to this ratio where appropriate. Linear regression
of the log mean O/E on strata and arm (2-way ANOVA)
will be used to estimate the risk/rate ratio and 95% CI
associated with the intervention. The variance for the ratio
of mean O/E is calculated from the residual mean square
from an ANOVA of O/E on strata and arm.
For the continuous outcomes such as intervention costs
and stigma levels, linear regression of the mean number/
score will be used to adjust for confounders at the individ-
ual level. The regression model will include terms for the
adjustment factors and strata, but not study arm. For each
community the fitted model will be used to obtain the dif-
ference between observed and expected number of events.
Linear regression of the difference O-E on strata and arm
(2-way ANOVA) will be used to estimate the difference in
(O-E) between arms and the 95% CI associated with the
intervention. For all analyses, the robustness of the
assumptions will be confirmed by a non-parametric strat-
ified permutation test.
Analyses will also look at effects stratified by urban/rural
classification, TB notification rates, ART usage, size of
community and HIV prevalence. It is recognised that the
study has low power to detect differences by subgroup and
also the interaction between the interventions (ECF plus
HH Vs standard TB/HIV control activities) and so the
results of such analyses will be interpreted with caution.
Ethical considerations
The research ethics committees of the University of Zam-
bia, Stellenbosch University and the London School of
Hygiene and Tropical Medicine have approved the study.
Ongoing review and approval of the study will be main-
tained by these committees.
Community advisory boards representing community
members have been established in all 24 communities.
Permission for the study has also been obtained from
national, provincial, district and local health and educa-
tion authorities, community leaders and traditional lead-
ers.
All individuals receiving the household intervention and
all of those who participate in outcome measurement
such as prevalence surveys, tuberculin surveys and sec-
ondary outcome cohort visits will also be asked to provide
individual written informed consent.
A Data Safety and Monitoring Board has been established
for all of the CREATE trials to monitor data from the trials.
Regular trial monitoring is also carried out by the CREATE
Consortium as study sponsor.
All communities will benefit from strengthened TB care
and combined TB/HIV interventions that will ensure
more linkages between the TB and HIV programmes and
enable improved access to HIV care and especially ART.
This study is embedded within the governmental health
system in every health centre to ensure that these benefits
are sustained.
Discussion
ZAMSTAR is a trial of two complex public health interven-
tions to assess whether either or both can reduce the prev-Page 8 of 10
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complex interventions, especially when the disease tar-
geted is infectious, requires the use of a community-ran-
domised design. We anticipate that the interventions will
act at the individual, household and community levels by
finding more cases of tuberculosis more quickly and that
this will firstly reduce transmission of tuberculosis in the
household and the community and ultimately the preva-
lence of infection and disease. To enable us to capture all
of these steps in the process requires that we also measure
the outcomes for individuals, households and communi-
ties. We hope that by addressing the two diseases, TB and
HIV, together we will also have an impact on HIV. We
anticipate that our interventions will allow more individ-
uals to learn their HIV status and to either protect them-
selves from acquiring HIV or to access necessary HIV care.
We do not believe, however, that these interventions will
be able to significantly reduce HIV incidence or preva-
lence at the community level but do hope to be able to
show a reduction in incidence at the household level.
To increase trial efficiency, clusters in community ran-
domised trials should be numerous and small[19]. In the
context of the ZAMSTAR trial, however, we needed to bal-
ance this requirement with knowledge about the trans-
mission of tuberculosis within populations. We believe
that to measure effects on transmission and prevalence
requires the use of large clusters that encompass entire
and discrete populations, so that we can be fairly confi-
dent that any case of incident TB was caused by transmis-
sion from someone else in that community who had
access to the intervention. Due to the necessity to embed
the interventions within the existing health services, this
dictated that we use the entire population attending one
health centre as our community. Consequently although
we only have 24 communities, they have a combined
population of approximately 1.2 million. A 2 × 2 factorial
design allows us to evaluate the two interventions at the
same time, thus maximising the cost-efficiency of con-
ducting such a large trial.
Contamination of a community by a neighbouring com-
munity with a different set of interventions was a concern
and so the communities needed to be geographically and
culturally distinct. Mobility into and out of the communi-
ties may also dilute the effect of the interventions and we
tried to avoid communities that had high levels of mobil-
ity and are using census and qualitative studies to measure
the degree of mobility. Additionally we needed to use
communities that had high baseline levels of disease to
allow us to measure the impact of the interventions, but
we wished to maintain a range of urban and rural commu-
nities to retain generalisability. Combining these require-
ments has resulted in widely-spaced communities, using
seven different languages and with many different cul-
tures. Health and other infrastructures in these communi-
ties are generally poor, generating logistical challenges to
conducting the study. Gaining community trust is a proc-
ess that requires perseverance and understanding on the
part of both researchers and community members. With-
out trust there will not be widespread community involve-
ment in the study, which is necessary to ensure that the
interventions work well.
As well as the logistical and field work challenges raised by
such a study, there are statistical and design challenges.
While the factorial design is cost-efficient, allowing us to
evaluate the impact of two interventions in one trial [20],
the primary analysis will be based on comparisons of the
12 communities with an intervention vs the 12 without
this intervention. We are also powered to measure the
combined effect of the two interventions compared with
the control arm [arm 1 with arm 4], but not to compare
the interventions with each other. A specific consideration
in the analysis of factorial trials is the effect of interaction
between the interventions and whether this can be accu-
rately measured[21]. It is possible that the ECF interven-
tion will have a larger effect on the primary outcome when
combined with the HH intervention, and similarly the
HH intervention will be applied to more households if
more cases of TB are found using ECF. We do not believe
that there will be a significant negative interaction
between the two interventions and consider that both
interventions will have independent effects. We acknowl-
edge, however, that we will have limited power to detect
interactions between the interventions.
The small sample size also affected our choice of randomi-
sation strategies. Stratification and restricted randomisa-
tion were necessary to ensure balance between the arms of
the trial and to reduce the between-community coefficient
of variation[22].
Despite these challenges the study is underway and the
interventions appear to be feasible and popular. One of
the study's strengths is that it is embedded within the
existing health services, working closely with district and
provincial health teams and with clinic staff. The variety of
cultures and infrastructure ensures that the results will be
generalisable and we can already see that the interven-
tions could be applied in the routine health setting. The
primary outcome of the study, TB prevalence, will not be
measured until 2010, but already important knowledge is
being generated that is helping us understand the com-
plex epidemiology of the TB/HIV epidemic. The results of
this trial will provide much needed evidence for health
policy makers as they strive to control TB and HIV.Page 9 of 10
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